EUVIMEDEUVIMED entdecken
Crossref

TERAPIA CAR-T EM NEOPLASIAS HEMATOLÓGICAS: AVANÇOS, TOXICIDADES E PERSPECTIVAS FUTURAS

Pedro Everson Alexandre de Aquino, Thiago Mesquita Cândido, Mayara Freire de Alencar, Anderson Braga Rodrigues, Alannya Evelin Falcão Queiroz, Alicia Valessa Silva Bezerra, Ana Cristina Freitas Xavier, Ana Kelly Holanda da Silva, Andressa Sales Moura, Bianca Teixeixa Veras, Emanuele Araujo Rodrigues, Gisele Rocha de Sousa und 4 weitere

LUMEN ET VIRTUS · 13.07.2026 · 17 (62) · e13776

DOI: 10.56238/levv17n62-020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LUMEN ET VIRTUS, online erschienen am 13.07.2026. Verfasst von Pedro Everson Alexandre de Aquino und 15 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematological malignancies comprise a heterogeneous group of malignant diseases originating from hematopoietic and lymphatic cells, including leukemias, lymphomas, and multiple myeloma. Despite advances in chemotherapy, radiotherapy, monoclonal antibodies, targeted inhibitors, and hematopoietic stem cell transplantation, patients with relapsed or refractory disease still have poor prognosis and limited therapeutic options. In this context, chimeric antigen receptor T-cell therapy, known as CAR-T therapy, has emerged as one of the main innovations in contemporary cancer immunotherapy. This study aims to analyze, through an integrative literature review, the clinical advances, main toxicities, and future perspectives of CAR-T therapy in the treatment of hematological malignancies. This is an integrative review with a qualitative and exploratory approach, based on the analysis of scientific publications selected between 2017 and 2026, organized from an initial corpus gathered by the authors and complemented by a directed bibliographic search. The literature synthesis shows that CAR-T therapy has achieved expressive results in B-cell malignancies and multiple myeloma, especially through CD19 and BCMA targets. However, its clinical application remains limited by toxicities such as cytokine release syndrome, immune effector cell-associated neurotoxicity, cytopenias, infections, as well as challenges related to tumor relapse, antigen escape, high cost, individualized manufacturing, and restricted access. It is concluded that CAR-T therapy represents a paradigm shift in onco-hematology, but its consolidation depends on improving cellular products, early management of toxicities, and expanding strategies capable of making this technology safer, more durable, and more accessible.

Zitieren

APA

Aquino, P. E. A. D., Cândido, T. M., Alencar, M. F. D., Rodrigues, A. B., Queiroz, A. E. F., Bezerra, A. V. S., Xavier, A. C. F., Silva, A. K. H. D., Moura, A. S., Veras, B. T., Rodrigues, E. A., Sousa, G. R. D., Rocha, J. G., Souza, M. Y. D. L., Leitão, S. D. A., & Oliveira, M. T. A. (2026). TERAPIA CAR-T EM NEOPLASIAS HEMATOLÓGICAS: AVANÇOS, TOXICIDADES E PERSPECTIVAS FUTURAS. LUMEN ET VIRTUS, 17(62), e13776. https://doi.org/10.56238/levv17n62-020

Vancouver

Aquino PEAD, Cândido TM, Alencar MFD, Rodrigues AB, Queiroz AEF, Bezerra AVS, et al. TERAPIA CAR-T EM NEOPLASIAS HEMATOLÓGICAS: AVANÇOS, TOXICIDADES E PERSPECTIVAS FUTURAS. LUMEN ET VIRTUS. 2026;17(62):e13776. doi:10.56238/levv17n62-020

BibTeX
@article{Aquino2026,
  author = {Aquino, Pedro Everson Alexandre de and Cândido, Thiago Mesquita and Alencar, Mayara Freire de and Rodrigues, Anderson Braga and Queiroz, Alannya Evelin Falcão and Bezerra, Alicia Valessa Silva and Xavier, Ana Cristina Freitas and Silva, Ana Kelly Holanda da and Moura, Andressa Sales and Veras, Bianca Teixeixa and Rodrigues, Emanuele Araujo and Sousa, Gisele Rocha de and Rocha, Josiane Gomes and Souza, Marcos Yuri de Lima and Leitão, Sarah de Azevedo and Oliveira, Maria Tatiana Alves},
  title = {TERAPIA CAR-T EM NEOPLASIAS HEMATOLÓGICAS: AVANÇOS, TOXICIDADES E PERSPECTIVAS FUTURAS},
  journal = {LUMEN ET VIRTUS},
  year = {2026},
  volume = {17},
  number = {62},
  pages = {e13776},
  doi = {10.56238/levv17n62-020}
}
Kostenlos starten →